Rocket Pharmaceuticals, based in Cranbury, New Jersey, develops gene therapies for rare pediatric diseases and employs 268 people. The company targets conditions like Fanconi Anemia and Leukocyte Adhesion Deficiency-I.
Rocket Pharmaceuticals (RCKT) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Rocket Pharmaceuticals's actual EPS was -$0.62, beating the estimate of -$0.73 per share, resulting in a 15.35% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
